AIMT
Aimmune Therapeutics
AIMT
AIMT
Delisted
AIMT was delisted on the 12th of October, 2020.
151 hedge funds and large institutions have $1.25B invested in Aimmune Therapeutics in 2018 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 69 increasing their positions, 35 reducing their positions, and 26 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more call options, than puts
Call options by funds: $ | Put options by funds: $
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
15% less capital invested
Capital invested by funds: $1.48B → $1.25B (-$228M)
29% less funds holding in top 10
Funds holding in top 10: 7 → 5 (-2)
Holders
151
Holding in Top 10
5
Calls
$7.2M
Puts
$4.19M
Top Buyers
| 1 | +$16.4M | |
| 2 | +$15.2M | |
| 3 | +$14M | |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$9.54M |
| 5 |
Morgan Stanley
New York
|
+$6.53M |
Top Sellers
| 1 | -$28.7M | |
| 2 | -$18.5M | |
| 3 | -$17.5M | |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$9.77M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$9.47M |